- Home
- FRPT vs DNLI Comparison
FRPT vs DNLI Comparison
Compare FRPT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRPT | DNLI |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FRPT | DNLI |
|---|---|---|
| Price | $80.21 | $20.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $74.53 | $30.80 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.87 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $1,102,015,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $9.49 | $3,886.00 |
| P/E Ratio | $39.37 | ★ N/A |
| Revenue Growth | ★ 13.01 | N/A |
| 52 Week Low | $46.76 | $10.57 |
| 52 Week High | $111.62 | $23.77 |
Technical Indicators
Market Signals| Indicator | FRPT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 75.86 | 57.99 |
| Support Level | $78.03 | $13.29 |
| Resistance Level | $83.52 | $23.77 |
| Average True Range (ATR) | 3.39 | 1.20 |
| MACD | 0.82 | -0.05 |
| Stochastic Oscillator | 83.57 | 69.29 |
Price Performance
Historical ComparisonAbout FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.